- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06125743
Autocuidado del linfedema y fibrosis de cabeza y cuello [ensayo PROMISE]
Promoción del autocuidado en supervivientes de cáncer de cabeza y cuello con linfedema y fibrosis [ensayo PROMISE]
The goal of this study is to evaluate the effectiveness of a standardized lymphedema and fibrosis self-management program (LEF-SMP) to improve LEF self-management and reduce LEF-associated symptom burden, functional deficits, and improve quality of life in head and neck cancer (HNC) survivors.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
In HNC survivors with lymphedema and fibrosis (LEF), the investigators will: 1) compare the effects of in-person LEF-SMP, telehealth LEF-SMP, and usual care on LEF severity; 2) compare the effects of in-person LEF-SMP, telehealth LEF-SMP, and usual care on LEF-related symptom burden, functional impairments, and quality of life; and 3) compare the effects of in-person LEF-SMP, telehealth LEF-SMP, and usual care on LEF-related knowledge, skills, self-efficacy, and self-care adherence.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jie Deng, PhD
- Número de teléfono: 2155732393
- Correo electrónico: jiedeng@nursing.upenn.edu
Ubicaciones de estudio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- University of Pennsylvania
-
Contacto:
- Jie Deng, PhD
- Número de teléfono: 215-573-2393
- Correo electrónico: jiedeng@nursing.upenn.edu
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37303
- Reclutamiento
- Vanderbilt University Medical Center
-
Contacto:
- Barbara Murphy, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- >18 years of age
- Post HNC primary treatment
- No evidence of cancer (NED)
- Completion of initial lymphedema therapy for head and neck lymphedema
- Unable to obtain lymphedema therapy due to barriers noted above
- History of lymphedema on the face and neck, with or without fibrosis
- Ability to understand English in order to complete questionnaires
- Ability to perform self-care activities for LEF management
- Ability to provide informed consent
- Having an electronic device (a computer, tablet, iPad, or smartphone) and internet access at home
- A valid email address
Exclusion Criteria:
- Recurrent or metastatic cancer
- Any other active cancer
- Acute infection
- Acute congestive heart failure
- Acute renal failure
- Cardiac or pulmonary edema
- Sensitive carotid sinus
- Severe carotid blockage
- Uncontrolled hypertension
- Venous thrombosis
- Pregnant people
- Incarcerated patients
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: Cuidado usual
|
Participants will conduct self-care activities prescribed by their treating lymphedema therapists. |
|
Experimental: LEF-SMP en persona
|
Participants will receive the in-person LEF-SMP intervention. |
|
Experimental: Telesalud LEF-SMP
|
Participants will receive the telehealth LEF-SMP intervention. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in severity of lymphedema and fibrosis
Periodo de tiempo: Baseline, 3-, 6-, and 9-months post-intervention
|
This outcome measure will be assessed via Head and Neck - External Lymphedema and Fibrosis Assessment Criteria (HN-LEF Assessment Criteria). The total severity score of lymphedema and fibrosis (LEF) is calculated by summing the severity score (normal = 0, mild =1, moderate =2, and severe =3) of each anatomical site affected by head and neck LEF. Higher scores mean a worse outcome. |
Baseline, 3-, 6-, and 9-months post-intervention
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in severity of symptom burden
Periodo de tiempo: Baseline, 3-, 6-, and 9-months post-intervention
|
This outcome measure will be assessed via Head and Neck - Lymphedema and Fibrosis Symptom Inventory (HN-LEF Symptom Inventory). The severity score of symptom burden is dependent on the number of self-reported symptoms [overall score range: 0 (no) - 5 (severe)], and higher scores mean a worse outcome. |
Baseline, 3-, 6-, and 9-months post-intervention
|
|
Changes in degrees of jaw range of motion
Periodo de tiempo: Baseline, 3-, 6-, and 9-months post-intervention
|
This outcome measure will be assessed via Jaw Range of Motion Scale. Higher degrees of jaw range of motion mean a better outcome (criteria for trismus: mouth opening < 35mm). |
Baseline, 3-, 6-, and 9-months post-intervention
|
|
Changes in degrees of cervical range of motion
Periodo de tiempo: Baseline, 3-, 6-, and 9-months post-intervention
|
This outcome measure will be assessed via Cervical Range of Motion Instrument. Higher degrees of cervical range of motion mean a better outcome. |
Baseline, 3-, 6-, and 9-months post-intervention
|
|
Changes in quality-of-life score
Periodo de tiempo: Baseline, 3-, 6-, and 9-months post-intervention
|
This outcome measure will be assessed via European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). This questionnaire includes a global health-related quality of life scale, 5 functional subscales, 3 symptom scales, and 6 single items. Scores for all scales and single items are linearly converted to range from 0-100, and higher scores signify a higher quality of life. |
Baseline, 3-, 6-, and 9-months post-intervention
|
|
Changes in LEF-related knowledge score
Periodo de tiempo: Baseline, 3-, 6-, and 9-months post-intervention
|
LEF-related knowledge will be assessed via HN-LEF Knowledge Test scale. The scale asks participants to answer 35 true/false questions. The total score (score range: 0-35) represents participants' knowledge level related to head and neck LEF, and higher scores mean a better outcome. |
Baseline, 3-, 6-, and 9-months post-intervention
|
|
Changes in LEF-related skills
Periodo de tiempo: Baseline, 3-, 6-, and 9-months post-intervention
|
LEF-related skills will be assessed via HN-LEF Skill Checklist. Study lymphedema therapists use this checklist to evaluate participants' LEF self-care skills. |
Baseline, 3-, 6-, and 9-months post-intervention
|
|
LEF-related self-efficacy score
Periodo de tiempo: Baseline, 3-, 6-, and 9-months post-intervention
|
LEF-related self-efficacy will be assessed via Perceived Medical Condition Self-Management Scale [8-item, each item score 1 (strongly disagree) - 5 (strongly agree)]. Higher scores indicate greater self-efficacy. |
Baseline, 3-, 6-, and 9-months post-intervention
|
|
LEF-related self-care adherence status
Periodo de tiempo: Baseline, 3-, 6-, and 9-months post-intervention
|
LEF-related self-care adherence will be assessed via LEF Self-Care Checklist. Higher scores indicate greater better adherence to LEF self-care activities (i.e., full adherence: ≥ 5 days; partial adherence: 3-4 days; non-adherence: <3 days). |
Baseline, 3-, 6-, and 9-months post-intervention
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- UPCC# 12323
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .